Tumori, Gridelli: "With immunotherapy 27% death risk reduction"
Thus Cesare Gridelli, Director of the U.O.C. di Oncologia Medica dell'Impresa Ospedaliera 'Moscati' di Avellino, intervening in connection today in Milan..
- Center-right1
- Agency1
1 agency rewrite / co-publication detected
Summary
"Immunotherapy was first experienced in advanced stages of disease, where it demonstrated important benefits in terms of survival. Tumori, Gridelli: "With immunotherapy 27% death risk reduction.". There is already experience in Italy with an Eap, a so-called ‘compassionate use’ program, with more than 400 patients.
Furthermore, Durvalumab - concludes - was registered in Italy as an innovative drug by regulators because it changes the natural history of the disease". This has reduced the number of relapses.
Cross-referenced from 2 sources.
Factual coreconfirmed by several independent voices
"Immunotherapy was first experienced in advanced stages of disease, where it demonstrated important benefits in terms of survival.
reliability low1/2 sourcesTumori, Gridelli: "With immunotherapy 27% death risk reduction.".
reliability low1/2 sourcesThere is already experience in Italy with an Eap, a so-called ‘compassionate use’ program, with more than 400 patients.
reliability low1/2 sourcesDurvalumab - concludes - was registered in Italy as an innovative drug by regulators because it changes the natural history of the disease".
reliability low1/2 sourcesThis has reduced the number of relapses.
reliability low1/2 sources
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.